682 results
-
List item
Herbal medicinal product: Vitis viniferae folium
Vitis vinifera L., Grapevine Leaf, F: Assessment finalised, Last updated: 05/01/2018Vitis viniferae folium Circulatory … Vitis viniferae folium … public Grapevine leaf Vitis vinifera L., folium This … -
List item
Human medicine European public assessment report (EPAR): Opzelura
ruxolitinib phosphate, Vitiligo
Date of authorisation: 19/04/2023, Revision: 1, Authorised, Last updated: 22/06/2023Connective Tissue Diseases Vitiligo … for treating non-segmental vitiligo, a disease that causes patches … the body. In patients with vitiligo, the immune system (the body’s … -
List item
National expert: Marco Felici, Medicines Evaluation Board (updated)
- Declaration of interests - 39.21 KB | PDF
- Curriculum Vitae - 23.21 KB | PDF
Marco Felici … Marco Felici … Vitae Personal information Marco Felici Work experience … -
List item
National expert: Marco Cavaleri, European Medicines Agency (updated)
- Declaration of interests - 39.2 KB | PDF
- Curriculum Vitae - 265.26 KB | PDF
Marco Cavaleri … Marco Cavaleri … Vitae Personal information Marco Cavaleri Work experience … -
List item
National expert: Marco Greco, European Medicines Agency (updated)
- Declaration of interests - 43.65 KB | PDF
- Curriculum Vitae - 29.48 KB | PDF
Marco Greco … Marco Greco … Vitae Personal information Marco Greco Work experience … -
List item
National expert: Marco Fulfaro, Italian Medicines Agency (updated)
- Declaration of interests - 39.2 KB | PDF
- Curriculum Vitae - 23.56 KB | PDF
Marco Fulfaro … Marco Fulfaro … Vitae Personal information Marco Fulfaro Work experience … -
List item
National expert: Marcos Timón, The Spanish Agency Of Medicines And Medical Devices (updated)
- Declaration of interests - 40.1 KB | PDF
- Curriculum Vitae - 36.33 KB | PDF
Marcos Timón … Marcos Timón … Vitae Personal information Marcos Timón Work experience … -
List item
National expert: Marco Franceschin, Italian Medicines Agency (updated)
- Declaration of interests - 39.21 KB | PDF
- Curriculum Vitae - 40.5 KB | PDF
Marco Franceschin … Marco Franceschin … Vitae Personal information Marco Franceschin Work experience … -
List item
National expert: Marco van Teijlingen, Medicines Evaluation Board (updated)
- Declaration of interests - 39.46 KB | PDF
- Curriculum Vitae - 23.12 KB | PDF
Marco van Teijlingen … Marco van Teijlingen … Vitae Personal information Marco van Teijlingen Work experience … -
List item
National expert: Marco Di Girolamo, Italian Medicines Agency (updated)
- Declaration of interests - 39.3 KB | PDF
- Curriculum Vitae - 24.79 KB | PDF
Marco Di Girolamo … Marco Di Girolamo … Vitae Personal information Marco Di Girolamo Work experience … -
List item
National expert: Karl de Marco, Medicines Authority (updated)
- Declaration of interests - 39.21 KB | PDF
- Curriculum Vitae - 24.59 KB | PDF
Karl de Marco … Karl de Marco … Vitae Personal information Karl de Marco Work experience … -
List item
National expert: Marco Panero Bertucci, The Spanish Agency Of Medicines And Medical Devices (updated)
- Declaration of interests - 39.21 KB | PDF
- Curriculum Vitae - 36.59 KB | PDF
Marco Panero Bertucci … Marco Panero Bertucci … Vitae Personal information Marco Panero Bertucci Work experience … -
List item
Human medicine European public assessment report (EPAR): Opdualag
nivolumab, Relatlimab, Melanoma
Date of authorisation: 15/09/2022,
, Authorised, Last updated: 17/10/2022
-
List item
National expert: Alessandro Loppini, Italian Medicines Agency (updated)
- Declaration of interests - 39.67 KB | PDF
- Curriculum Vitae - 52.9 KB | PDF
-
List item
Orphan designation: Recombinant human insulin-like growth factor-I, recombinant human insulin-like growth factor binding protein-3 for: Treatment of type B extreme insulin resistance syndrome
Date of designation: 20/10/2004, Withdrawn, Last updated: 20/02/2009syndrome, alopecia areata, vitiligo, arthritis, nephritis, primary … syndrome, alopecia areata, vitiligo, arthritis, nephritis, primary … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Ruxolitinib (phosphate)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Dermatology
PIP number: EMEA-002618-PIP02-20, Route(s) of administration: Cutaneous use, Pharmaceutical form(s): Cream
Decision date: 16/04/2021, Last updated: 13/01/2022, Compliance check: Xindication(s) Treatment of vitiligo Route(s) of administration … Condition(s): Treatment of vitiligo Pharmaceutical form(s … Condition: Treatment of vitiligo The waiver applies to … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Zuretinol (acetate)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Ophthalmology
PIP number: EMEA-001453-PIP01-13-M01, Route(s) of administration: Oral use, Pharmaceutical form(s): Oral solution
Decision date: 05/10/2016, Last updated: 24/11/2016, Compliance check: XOphthalmics (UK) Ltd E-mail: marco@retinagenix.com Tel. +1 7863 5214 99 PM … -
List item
Orphan designation: Aganirsen for: Treatment of central retinal vein occlusion
Date of designation: 10/06/2014, Positive, Last updated: 10/07/2014Fax +33 155 6012 56 E-mail: marconi@voisinconsulting.com … 33 155 6012 56 E-mail: marconi@voisinconsulting.com For contact details … -
List item
Instrument for Pre-accession Assistance project 2011-2013
Last updated: 22/02/201301/01/2009 Generic Contact point marco.capellino@ema.europa.eu …
-
List item
Public stakeholder meeting: approval, safety monitoring and impact of COVID-19 vaccines in the EU
Virtual meeting, 13:00 - 15:15 (CET), 26/03/2021, Last updated: 14/04/2021COVID-19 vaccines in the EU, Marco Cavaleri (EMA … COVID-19 vaccines in the EU Marco Cavaleri (Head of Biological … COVID-19 vaccines in the EU Dr. Marco Cavaleri Head of Biological … -
List item
Public stakeholder meeting: development and authorisation of safe and effective COVID-19 vaccines in the EU
Virtual meeting, 11/12/2020, Last updated: 11/12/2020COVID-19 vaccines developed? (Marco Cavaleri) PDF icon application/pdf … COVID-19 vaccines developed? Marco Cavaleri (Head of Biological … vaccines developed? Dr. Marco Cavaleri Head of Biological … -
List item
National expert: Carole Schummer, Ministere De La Sante Division De La Pharmacie Et Des Medicaments (updated)
- Declaration of interests - 39.39 KB | PDF
- Curriculum Vitae - 21.27 KB | PDF
Ministere De L Agriculture De La Viticulture Et Du Developpement Rural Country … -
List item
Reinforcing communication with patients and healthcare professionals
Belgrade, Serbia, 23/06/2014, Last updated: 08/07/2014marco.capellino@ema.europa.eu … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023
CHMP, Last updated: 24/02/2023treatment of non-segmental vitiligo, a skin disorder characterised … -
List item
National expert: Aranzazu Sancho-Lopez, The Spanish Agency Of Medicines And Medical Devices (updated)
- Declaration of interests - 44.77 KB | PDF
- Curriculum Vitae - 38.06 KB | PDF
product related ruxolitinib vitiligo 1.3 Strategic advisory role No …